Open access
Aug 2026
CD161 serves as a prognostic biomarker and predicts immunotherapy response in head and neck squamous cell carcinoma
Background Despite advances in immune checkpoint inhibitors (ICIs), the prognosis of patients with head and neck squamous cell carcinoma (HNSCC) remains poor, and reliable biomarkers for predicting clinical outcomes are still lacking. CD161, a lectin-like receptor expressed on multiple T-cell subsets, has been reported...
Shuai Mei, Xiaoyan Qian, Hai-Zhu Chen et al.
· Frontiers in Immunology · 0 citations